Home | About CytoJournalEditorial Board | Archived articles | Search CytoJ Articles | Subscribe | Peer review policies | CytoJournal Quiz Cases
  Reviewer corner | Author corner | OA Steward’s corner | CF member’s corner | Join as CF member | Manuscript submission | Open Access (OA) Advocacy
CytoJournal All 'FULL TEXT' in HTML are FREE under "open access" charter of CytoJournal.
To login for downloading any PDF OR to request TOC (Table of Content) by e-mail, please click here
Home Email this page Print this page Small font size Default font size Increase font size Cytopathology Foundation
Navigate here
Resource links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »  Article in PDF (2,027 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)  

  In this article
 »  Abstract
 » Introduction
 » Case Report
 » Discussion
 » Conclusion
 »  Competing Intere...
 »  Authorship State...
 »  Ethics Statement...
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    PDF Downloaded13    
    Comments [Add]    
    Cited by others 3    

Recommend this journal


Browse articles
CytoJournal 2012,  9:16

An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV -positive, cirrhotic patient, and review of the literature

1 Department of Pathology and Cytology, University-Hospital of Larissa, 41110 Larissa, Greece
2 Department of Pathology and Cytology, University-Hospital of Larissa, 41110 Larissa; Department of Pathology, Democritus University of Thrace, University-Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece
3 Department of Gastroenterology, University-Hospital of Larissa, 41110 Larissa, Greece

Date of Submission03-Feb-2012
Date of Acceptance24-May-2012
Date of Web Publication29-Jun-2012

Correspondence Address:
Charitini Nepka
Department of Pathology and Cytology, University-Hospital of Larissa, 41110 Larissa
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1742-6413.97766

Rights and Permissions

 » Abstract 

Primary effusion lymphoma (PEL) is an unusual, human herpes virus-8 (HHV-8)−associated type of lymphoma, presenting as lymphomatous effusion in body cavities, without a detectable tumor mass. It primarily affects human immunodeficiency virus (HIV)-infected patients, but has also been described in other immunocompromised individuals. Although PEL is a B-cell lymphoma, the neoplastic cells are usually of the 'null' phenotype by immunocytochemistry. This report describes a case of PEL with T-cell phenotype in a HIV-negative patient and reviews all the relevant cases published until now. Our patient suffered from cirrhosis associated with Hepatitis Β virus (HΒV) infection and presented with a large ascitic effusion, in the absence of peripheral lymphadenopathy or solid mass within either the abdomen or the thorax. Paracentesis disclosed large lymphoma cells with anaplastic features consisting of moderate cytoplasm and single or occasionally multiple irregular nuclei with single or multiple prominent nucleoli. Immunocytochemically, these cells were negative for both CD3 and CD20, but showed a positive reaction for T-cell markers CD43 and CD45RO (VCHL-1). Furthermore, the neoplastic cells revealed strong positivity for EMA and CD30, but they lacked expression of ALK-1, TIA-1, and Perforin. The immune status for both HHV-8 and Epstein-Barr virus (EBV) was evaluated and showed positive immunostaining only for the former. The combination of the immunohistochemistry results with the existence of a clonal rearrangement in the immunoglobulin heavy chain gene (identified by PCR), were compatible with the diagnosis of PEL. The presence of T-cell markers was consistent with the diagnosis of PEL with an aberrant T-cell phenotype.

Keywords: Cirrhosis, HHV-8, HIV, HΒV, primary effusion lymphoma

How to cite this article:
Nepka C, Kanakis D, Samara M, Kapsoritakis A, Potamianos S, Karantana M, Koukoulis G. An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV -positive, cirrhotic patient, and review of the literature. CytoJournal 2012;9:16

How to cite this URL:
Nepka C, Kanakis D, Samara M, Kapsoritakis A, Potamianos S, Karantana M, Koukoulis G. An unusual case of Primary Effusion Lymphoma with aberrant T-cell phenotype in a HIV-negative, HBV -positive, cirrhotic patient, and review of the literature. CytoJournal [serial online] 2012 [cited 2019 Dec 7];9:16. Available from: http://www.cytojournal.com/text.asp?2012/9/1/16/97766

Editorial / Peer-Review Statement: To ensure the integrity and highest quality of CytoJournal publications, the review process of this manuscript was conducted under a double blind model (authors are blinded for reviewers and vice versa) through an automatic online system.

 » Introduction Top

It was Cesarman and colleagues. in 1995, who first identified KSHV DNA sequences within a distinct subgroup of AIDS-related non-Hodgkin lymphomas (NHL) localized in body cavities, presenting as lymphomatous effusions. [1] Subsequently, Nador et al. (1996) introduced the term 'primary effusion lymphoma' (PEL) in order to describe this particular type of lymphoma, which was lacking a tumor mass, but was accompanied by HHV- 8 infection. [2] According to the definition provided by the World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues (issue 2008), the primary effusion lymphoma is a large B-cell neoplasm that usually presents as a serous effusion without a detectable tumor mass and is universally associated with HHV-8. Some patients with PEL, secondarily develop solid tumors in the adjacent structures, such as, the pleura, whereas, rare cases of HHV-8-positive lymphomas (indistinguishable from PEL) present as solid tumor masses, and have acquired the designation of extracavitary PEL. [3] Furthermore, PEL is included in the category of HIV-associated lymphomas, having been referred in the literature as 'lymphomas occurring more specifically in HIV-positive patients', [4] although it has been almost simultaneously reported in HIV-negative patients also. [5],[6],[7] In this setting PEL has been linked to other immunodeficiency conditions, such as, following an organ transplantation, [8],[9],[10] cancer, [11],[12] old age, [13],[14] or even cirrhosis. [15],[16] There are also published reports that describe PEL associated with liver cirrhosis and as a simultaneous infection with either Hepatitis B or C virus. [17],[18]

As far as cytomorphology is concerned, PEL shows features bridging immunoblastic and anaplastic large-cell lymphomas, with a frequent demonstration of plasma cell differentiation. Interestingly, PEL exhibits a 'null' immunophenotype, as it lacks expression of both B- and T-cell associated antigens. [5]

We herein report a case of HIV-negative PEL, with underlying Hepatitis B virus (HBV)-related liver cirrhosis, which additionally showed the relative infrequent immunocytochemical expression of T-cell associated antigens. Our case was also positive for HHV-8, a finding that along with the particular cytomorphological and immunocytochemical findings, confirmed that the lymphomatous effusion was a case of PEL.

 » Case Report Top

Clinical summary

The patient was an 88-year-old man of Mediterranean descent, with a history of cirrhosis and underlying HBV infection. At the time of presentation in the clinic, he complained of generalized weakness and fatigue over the last month. Physical examination revealed icterus of the skin and sclera, as well as abdominal distention, owing to the presence of ascitic fluid without any detectable hepatosplenomegaly.

The peripheral blood count showed macrocytic anemia (Hb: 11,6 g / dL, MCV: 108,0 fL), thrombocytopenia (PLT: 113 × 10 3 / μL) and normal WBC count and differential. In particular, the exact values were as follows: WBC: 4,0 × 10 3 / μL, Neut.: 72%, Lymph.: 18%, Mono.: 9,0%, Eosino.: 1,0%, RBC: 3,09 × 10 6 / μL, Hb: 11,6 g / dL, MCV: 108,0 fL, MCH: 37,6 pg, and PLT: 113 × 10 3 / μL. His serum profile provided the following results: Gluc: 105,0 mg / dl, UREA: 32,0 mg / dL, CREAT: 0,88 mg / dL, SGOT: 223,0 U / L, SGPT: 155 U / L, T-Bil.: 7,0 mg / dL, Bl-Bil.: 3,0 mg / dL, γ-GTP: 50 U / L, ALP: 165 U / L, LDH: 241 U / L, Prot: 7,4 g / dL, Alb: 2,1 g / dL, CK: 183 U / L. The biochemical examination of the collected peritoneal fluid revealed: Gluc 111 mg / dL, Prot: 2,2 g / dL, Alb: 0,65 g / dL, LDH: 1590 U / L, Chol: 7,0 mg / dL, and Trigl: 16 mg / dL.

Abdominal Ultrasound-Sonography (US) demonstrated liver cirrhosis and massive ascites. Computed-Tomography (CT), which was carried out later confirmed the ascites, although with no visible peritoneal implants. Furthermore, no pathological lymphadenopathy was detected by the obtained CT-scans.

Paracentesis was performed, yielding a large amount (800 ml) of ascitic fluid that was subsequently sent for cytological evaluation. After centrifugation of the sample, the sediment was used for ThinPrep preparation as well as for routine preparation, with direct smearing stained with both Pap and Giemsa. The remaining sediment was used for cell block preparation, using the plasma-thrombin method and standard H and E staining.

Cytological findings

The Thin Prep material consisted of abundant large-sized malignant cells, with a moderate amount of basophilic cytoplasm, which were arranged singly. Most of them had a single nucleus, but occasionally, bi-nucleated or multinucleated cells were also seen. The nucleus had coarse chromatin pattern, irregular nuclear outlines, and a single or multiple prominent nucleoli. A high mitotic activity, with abnormal mitoses was present, and a large number of apoptotic bodies as well as nuclear debris were additionally seen [Figure 1]a and b.
Figure 1: (a) Cell block of FNA material showing a striking nuclear pleomorphism as well as a high mitotic index with irregular mitoses and numerous apoptotic bodies (H and E stain, magnification x200). (b) Higher magnification of the figure 1a, with particular emphasis on the details noted above (H and E stain, magnification x400)

Click here to view


The immunophenotypic profile of the tumor was determined by standard immunoperoxidase methods using paraffin sections from cell block material. The primary antibodies used were: AE1 / AE3, EMA, Vimentin, Melan A, MPO, Fascin, Perforin, Bcl-6, CD3, CD4, CD5, CD8, CD10, CD15, CD20, CD30, CD34, CD43, CD45 (LCA), CD45RO, and CD138 antigens. In addition, anaplastic lymphoma kinase 1 (ALK-1) protein, TIA-1, LMP-1, and HHV-8 (Latent Nuclear Antigen-1; LANA-1) were also investigated. Antigen retrieval was performed using ethylenediamine tetraacetic acid (EDTA)-based solution (CC1). The primary antibody, secondary antibody, and avidin-enzyme conjugate were then visualized using the precipitating enzyme diaminobenzidine (DAB). The detailed immunocytochemical list of the antibodies used in our case is depicted in [Table 1].
Table 1: Immunohistochemistry-results

Click here to view

Molecular analysis

A possible Epstein-Barr virus (EBV) infection was excluded using the EBV-encoded RNA (EBER) in situ hybridization test in cell block material. On the contrary, the infection with he Hepatitis B virus was further confirmed with the identification of the HBV-DNA. Moreover, sediment from the ascitic fluid was examined using the polymerase chain reaction (PCR) method to detect any clonal rearrangement of the immunoglobulin heavy chain gene (IgH). Moreover, we checked for gene rearrangement in the T-cell receptor. In particular, and in more detail, the methods used are described below and the obtained results are shown in the attached figures.

Molecular analysis was performed using the IdentiClone IgH Gene Clonality Assay kit (CE-IVD, InVivoScribe Technologies, USA). The DNA was extracted and amplified by primers that target the conserved framework of the variable (V) regions, the conserved joining (J) regions, as well as the diversity and joining regions, according to the manufacturer's instructions. The DNA quality was tested by the Specimen Control Size Ladder Mix, which contains multiple oligonucleotides targeting the housekeeping genes [supplied with the Kit, [Figure 3]].
Figure 2: The performed immunocytochemistry (ICC) revealed among others, a positive reaction in the neoplastic cell population for (a) CD30 (magnification x200), (b) CD43 (magnification x200), (c) CD45 (magnification x200), (d) CD45RO (magnification x200), (e) EMA (magnification x200), and (f) HHV-8 [LANA-1] (nuclear staining; magnification x200)

Click here to view
Figure 3: DNA quality control by Specimen Control Size ladder mix supplied with the kit. Samples at positions 1, 5, 6, 7, and 8 are controls supplied with the kit. Samples at positions 2, 3, and 4 are from patients. Sample 3 is the requested sample. Samples 2 and 4 have bad quality of DNA. M: PhiX174 / HaeIII digest ladder (New England Biolabs).

Click here to view

The presence or absence of clonal T-cell Receptor Gamma chain gene rearrangements was evaluated using the IdentiClone TCRG Gene Clonality Assay (CE-IVD, InVivoScribe Technologies, USA) according to the manufacturer's instructions, as mentioned earlier.

The PCR products were analyzed in agarose gel electrophoresis, followed by non-denaturing polyacrylamide gel electrophoresis (PAGE), in the presence of positive (clonal) and negative (polyclonal) controls [Figure 4], [Figure 5] and [Figure 6].
Figures 4: Identification of Clonal Immunoglobulin Heavy Chain Gene Rearrangements in non-denaturing polyacrylamide electrophoresis gels (PAGE). Positions 1 and 8 polyclonal controls, positions 2 −4, 9 − 11 samples, and positions 5 − 8, 12 − 16 clonal controls. Requested sample at positions 3 and 10.

Click here to view
Figure 5: Identification of Clonal Immunoglobulin Heavy Chain Gene Rearrangements in non-denaturing polyacrylamide electrophoresis gels. Positions 1 and 9 polyclonal controls, positions 2 − 4, 10 − 12 samples, positions 5 − 8, 13 − 15 clonal controls. Requested sample at positions 3 and 11. M: PhiX174 / HaeIII digest ladder (New England Biolabs).

Click here to view
Figure 6: Identification of Clonal T Cell Receptor Gamma Chain Gene Rearrangements in non-denaturing polyacrylamide electrophoresis gel (PAGE). Positions 1 and 9 polyclonal controls, positions 2 − 5, 10 − 13 samples, and positions 6 − 8, 14, and 15 clonal controls. Requested sample at positions 5 and 13. M: PhiX174 / HaeIII digest ladder (New England Biolabs).

Click here to view

Other laboratory tests

A bone-marrow aspirate showed no evidence of lymphoma. The serological investigation revealed the following results: HbsAg: (+), Anti-Hbc: IgG(+), Anti-Hbe: (-), HbeAg: (+), Anti-Hbs: (-), Anti-HCV: (-), and Anti-HIV: (-).

Final cytological diagnosis

The final diagnosis that was based on both cytological and immunocytochemical findings, in conjunction with the appropriate molecular workup, was indicative of primary effusion lymphoma with aberrant T-cell expression. The patient unfortunately died one week after the final diagnosis.

 » Discussion Top

Dissemination of Non-Hodgkin's lymphomas (NHL) in serous cavity fluids has been reported in approximately 10% of all malignant effusions. [19] The term PEL was initially introduced by Nador et al., in 1996, in order to describe a novel type of lymphoma, presenting exclusively as a lymphomatous effusion in the absence of a detectable solid mass. [2] In a majority of lymphoma cases other than PEL, a precise subtyping of the neoplasm in cytological specimens is not required, as the actual diagnosis will have been already established in the solid parts of the tumor, before the acquisition of the cytological sample. [20] However, on some occasions where the serous cavity effusion is more accessible relative to the primary site of involvement, the cytological and immunocytochemical interpretation is, without doubt, of outmost importance, especially when a PEL diagnosis is under consideration.

As we have already mentioned above, primary effusion lymphoma has a strong association with HHV-8 infection, but it also seems to have a relative 'preference' for occurrence in HIV-positive individuals. Indeed, this unique type of lymphoma has been estimated to account for approximately 4% of NHL in HIV-positive patients, but only for 0.3% of NHL in HIV-negative patients. [21] In these cases, where the patients are HIV negative (as in our case; see also review of all published so far [HHV-8(+) and HIV(-)] cases in [Table 2]), other immunodeficient conditions may exist. Our patient, although negative for HIV infection, presented with liver cirrhosis associated with Hepatitis B virus. Cirrhosis, which is an established condition of immunodeficiency, [49] has been described in association with PEL; specifically there are a few reports that demonstrate the presence of PEL together with liver cirrhosis. [15],[16],[47] Although a majority of PEL-cases referred to in literature are HHV-8 positive, [34] there are several examples in which the absence of HHV-8, with or without a simultaneous absence of HIV infection, has been observed. [50],[51],[52],[53] These particular cases have been further referred in the literature as 'HHV-8-unrelated PEL-like lymphomas', in order to differentiate them from 'true' PEL. Therefore, the presence of HHV-8 has been established almost as a criterion, to consider a lymphoma as a PEL, as the former is considered to play a crucial role in the pathogenesis of the latter. [34] In this context, it has been proposed that the name PEL should be assigned only to this primary lymphomatous effusion that shows evidence of HHV-8 infection, along with the supportive morphological and immunophenotypical criteria. [54],[55] The standard assay to detect HHV-8 infection in tissues is the immunocytochemical staining for LANA-1, [56] whereas, EBV infection is most reliably identified by in situ hybridization for EBV-RNA, as immunocytochemical staining for EBV latent membrane protein (LMP-1) is almost always negative. [3] Accordingly, after completion of the relative tests, our case has shown the presence of HHV- 8 and the absence of EBV infection. Previous molecular studies have approved the occurrence of immunoglobulin gene rearrangements (this is also true in our case) and somatic hypermutation in PEL cells, indicating that the cell of origin is a post-germinal center B-cell. [57]

[Additional file 1]

Similarly, the experiments carried out by Fais et al., further suggested that PEL originated from mature antigen-experienced B-cells. Specifically, this group performed sequencing-analysis in immunoglobulin (Ig) genes from seven AIDS-related PEL. The obtained results showed that most of the samples used lambda light chain genes, two cases expressed mu chains, whereas, gamma chains were also found in two cases. In all cases, significant deviations from the presumed germline counterpart were found in both the expressed VH and VL genes. Statistical evidence for antigen selection was evident in four out of the seven samples studied. Evidence for selection was more frequent in the light chain genes than in the heavy chain genes. [58] Gene expression profile analysis, which had already been performed in cases of AIDS-related PEL, had also confirmed a plasmablastic derivation. [36] The cells of PEL immunocytochemically exhibited an indeterminate or 'null' lymphocyte phenotype, a they showed positive staining for the leukocyte common antigen (LCA; CD45), but negative staining for both routine B-cell- (including surface and cytoplasmic immunoglobulin, CD19, CD20, CD79a) and T-cell-markers (CD3, CD4, CD8). Instead, various markers of lymphocyte activation (CD30, CD38, CD71, human leukocyte antigen DR) and plasma cell differentiation (CD138) are usually displayed. [54],[59],[60] Unlike the majority of reported cases, which show-as noted before-a 'null' immunophenotype, our case expressed, to a variable extend, T-cell markers (such as CD4, CD8, CD43; [Figure 2]b) and CD45RO [Figure 2]d, but showed no expression of the B-cell marker CD20.

The occurrence of a T-cell immunophenotype in PEL is a relatively rare event and only a few cases have been published until now. [33],[38],[47],[51],[61],[62] The differential diagnosis of PEL, on a cytomorphological ground, includes other large cell lymphomas, such as, anaplastic large cell lymphoma (ALCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), with plasmacytoid differentiation, and pyothorax-associated lymphoma (PAL). Among them, the Anaplastic Large Cell Lymphoma (ALCL) and PEL share similar morphological and immunocytochemical characteristics. Morphologically, they are both high-grade lymphomas, composed of large cells with pleomorphic nuclei and prominent single-to-multiple nucleoli. However, the typical 'hallmark cells' with the eccentric kidney- or horseshoe-shaped nuclei and a prominent Golgi zone, which have been previously described in ALCL, are only seldom seen in PEL. Immunocytochemically both are positive for CD30 and EMA. Furthermore, ALCL demonstrates a T-cell immunophenotype. With regard to all the arguments raised herewith, while keeping in mind that our case also showed a T-cell profile, it was particularly difficult to rule out an ALCL. However, the negative immunostaining for ALK-1, in conjunction with the strong positivity for HHV-8, as it was a fact in our case, rendered the diagnosis of PEL as the most plausible. [63] The exclusion of the rest of the lymphoma subtypes from the final diagnosis was more obvious. As far as Diffuse large B-cell lymphoma (DLBCL) and in particular the immunoblastic variant is concerned, confusion may arise, as this may also show morphological features similar to PEL. However, both the immunophenotype and HHV-8 detection are helpful in distinguishing these two entities, as DLBCL expresses B-cell markers and is HHV-8 negative. Unlike the classic Burkitt lymphoma (BL), the variant of BL with plasmacytoid differentiation, often seen in AIDS patients, may demonstrate common morphological characteristics with PEL. In these cases, immunophenotyping usually shows a B-cell lineage in BL compared with the common 'null'-phenotype of PEL or the rarer T-cell immunophenotype of our case. In addition, the negative staining for both CD10 and Bcl-6 as well as the simultaneous presence of HHV-8, all observed in the present case, did not correlate with the diagnosis of a BL. [64] Finally, pyothorax-associated lymphoma (PAL) is, as the term implies, a pleural EBV-associated NHL that develops after longstanding chronic pleural inflammation. Cytologically, PAL may be indistinguishable from PEL, thus immunophenotyping and HHV-8 testing are essential in this distinction. Indeed, PAL expresses B-cell markers, is HHV-8 negative, and even more it goes hand in hand with the presence of EBV. [64],[65]

 » Conclusion Top

All in all, the diagnosis of PEL should be kept in mind whenever lymphomatous effusions, without a detectable primary solid mass, are present and the immunodeficiency status is either evident or is speculated. In such cases, a concrete panel of immunohistochemical markers together with specific molecular studies should be carried out. However, the hallmark of this particular entity remains the identification of HHV-8 infection.

 » Competing Interest Statement by All Authors Top

No competing interest to declare by any of the authors.

 » Authorship Statement Made by All Authors Top

Each author acknowledges that this final version was read and approved. According to the International Committee of Medical Journal Editors (ICMJE http://www.icmje org) an 'author' is generally considered to be someone who has made substantive intellectual contributions to a published study. Authorship credit should be based on (1) substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions (1), (2), and (3). Other contributors, who do not meet these criteria for authorship, are listed in the 'acknowledgments' section. All authors of this article declare that they qualify for authorship as defined by ICMJE (http://www.icmje.org/#author). Each author has participated sufficiently in the study and takes public responsibility for the appropriate portions of the content of this article.

 » Ethics Statement by All Authors Top

As this is a case report without patient identifiers, approval from Institutional Review Board (IRB) is not required at our institution.

 » References Top

1.Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences are present in AIDS-related body-cavity-based lymphoma. N Engl J Med 1995;332:1186-91.  Back to cited text no. 1
2.Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al.. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's-sarcoma-associated herpes virus. Blood 1996;88:645-56.  Back to cited text no. 2
3.Said J, Cesarman E. Primary effusion lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization Classification of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. p. 260-1.  Back to cited text no. 3
4.Raphael M, Said J, Borisch B, Cesarman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. p. 340-2.  Back to cited text no. 4
5.Carbone Á, Gloghini A. KSHV / HHV8-associated lymphomas. Br J Haematol 2007;140:13-24.  Back to cited text no. 5
6.Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007;111:224-33.  Back to cited text no. 6
7.Yiakoumis X, Pangalis GA, Kyrtsonis MC, Vassilakopoulos TP, Kontopidou FN, Kalpadakis C, et al.. Primary Effusion Lymphoma in Two HIV-negative patients successfully treated with pleurodesis as first-line therapy. Anticancer Res 2010;30:271-6.  Back to cited text no. 7
8.Jones D, Ballestas ME, Kaye KM, Gulizia JM, Winters GL, Fletcher J, et al.. Primary- effusion lymphoma and Kaposi's sarcoma in a cardiac-transplant recipient. N Engl J Med 1998;339:444-9.  Back to cited text no. 8
9.Dotti G, Fiocchi R, Motta T, Facchinetti B, Chiodini B, Borleri GM, et al.. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8. Leukemia 1999;13:664-70.  Back to cited text no. 9
10.Boulanger E, Afonso PV, Yahiaoui Y, Adle-Biassette H, Gabarre J, Agbalika F. Human herpesvirus-8 (HHV-8)-associated primary effusion lymphoma in two renal transplant recipients receiving rapamycin. Am J Transplant 2008;8:707-10.  Back to cited text no. 10
11.Strauchen JA, Hauser AD, Burstein D, Jimenez R, Moore PS, Chang Y. Body cavity-based malignant lymphoma containing Kaposi sarcoma-associated herpesvirus in an HIV-negative man with previous Kaposi sarcoma. Ann Intern Med 1996;125:822-5.  Back to cited text no. 11
12.Ascoli V, Scalzo CC, Danese C, Vacca K, Pistilli A, Lo Coco F. Human herpes virus-8 associated primary effusion lymphoma of the pleural cavity in HIV-negative elderly men. Eur Respir J 1999;14:1231-4.  Back to cited text no. 12
13.Schulz TF. Epidemiology of Kaposi's sarcoma-associated herpesvirus / human herpesvirus. Adv Cancer Res 1999;76:121-60.  Back to cited text no. 13
14.Carbone A, Gloghini A. PEL and HHV8-unrelated effusion lymphomas: classification and diagnosis. Cancer 2008;114:225-7.  Back to cited text no. 14
15.Carbone A, Gloghini A, Vaccher E, Zagonel V, Pastore C, Dalla Palma P, et al.. Kaposi's sarcoma-associated herpesvirus DNA sequences in AIDS-related and AIDS-unrelated lymphomatous effusions. Br J Haematol 1996;94:533-43.  Back to cited text no. 15
16.Cobo F, Hernandez S, Hernandez L, Pinyol M, Bosch F, Esteve J, et al.. Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. J Pathol 1999;189:288-93.  Back to cited text no. 16
17.Hsieh PY, Huang SI, Li DK, Mao TL, Sheu JC, Chen CH. Primary effusion lymphoma involving both pleural and abdominal cavities in a patient with hepatitis B virus-related liver cirrhosis. J Formos Med Assoc 2007;106:504-8.  Back to cited text no. 17
18.Makis W, Stern J. Hepatitis C-related primary effusion lymphoma of the pleura and peritoneum, imaged with F-18 FDG PET / CT. Clin Nucl Med 2010;35:797-9.  Back to cited text no. 18
19.Malik I, Abubakar S, Rizwana I, Alam F, Rizvi J, Khan A. Clinical features and management of malignant ascites. J Pak Med Assoc 1991;41:38-40.  Back to cited text no. 19
20.Naylor B. Cytological aspects of pleural, peritoneal and pericardial fluids from patients with systemic lupus erythematosus. Cytopathology 1992;3:1-8.  Back to cited text no. 20
21.Gaidano G, Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled cavities. Adv Cancer Res 2001;80:115-46.  Back to cited text no. 21
22.Nador RG, Cesarman E, Knowles DM, Said JW. Herpes-like DNA sequences in a body-cavity-based lymphoma in an HIV-negative patient. N Engl J Med 1995;333:943.   Back to cited text no. 22
23.Said W, Chien K, Takeuchi S, Tasaka T, Asou H, Cho SK, et al.. Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. Blood 1996;87:4937-43.  Back to cited text no. 23
24.Teruya-Feldstein J, Zauber P, Setsuda JE, Berman EL, Sorbara L, Raffeld M, et al.. Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma. Lab Invest 1998;78:1637-42.  Back to cited text no. 24
25.Vu HN, Jenkins FW, Swerdlow SH, Locker J, Lotze MT. Pleural effusion as the presentation for primary effusion lymphoma. Surgery 1998;123:589-91.  Back to cited text no. 25
26.Okada T, Katano H, Tsutsumi H, Kumakawa T, Sawabe M, Arai T, et al.. Body-cavity-based lymphoma in an elderly AIDS-unrelated male. Int J Hematol 1998;67:417-22.  Back to cited text no. 26
27.San Miguel P, Manzanal A, Garcia Gonzalez R, Bellas C. Association of body cavity-based lymphoma and human herpesvirus 8 in an HIV-seronegative male. Report of a case with immunocytochemical and molecular studies. Acta Cytol 1999;43:299-302.  Back to cited text no. 27
28.Codish S, Abu-Shakra M, Ariad S, Zirkin HJ, Yermiyahu T, Dupin N, et al.. Manifestations of three HHV-8-related diseases in an HIV-negative patient: immunoblastic variant multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma. Am J Hematol 2000;65:310-4.  Back to cited text no. 28
29.Ariad S, Benaharroch D, Lupu L, Davidovici B, Dupin N, Boshoff C. Early peripheral lymph node involvement of human herpesvirus 8-associated, body cavity-based lymphoma in a human immunodeficiency virus-negative patient. Arch Pathol Lab Med 2000;124:753-5.  Back to cited text no. 29
30.Polskj JM, Evans HL, Grosso LE, Popovic WJ, Taylor L, Dunphy CH. CD7 and CD56-positive primary effusion lymphoma in a human immunodeficiency virus-negative host. Leuk Lymphoma 2000;39:633-9.  Back to cited text no. 30
31.Perez CL, Rudoy S. Anti-CD20 monoclonal antibody treatment of human herpesvirus 8-associated, body cavity-based lymphoma with an unusual phenotype in a human immunodeficiency virus-negative patient. Clin Diagn Lab Immunol 2001;8:993-6.  Back to cited text no. 31
32.Klepfish Á, Sarid R, Shtalrid M, Shvidel L, Berrebi A, Schattner A. Primary effusion lymphoma (PEL) in HIV-neagtive patients--a distinct clinical entity. Leuk Lymphoma 2001;41:439-43.  Back to cited text no. 32
33.Lechapt-Zalcman E, Challine D, Delfau-Larue MH, Haioun C, Desvaux D, Gaulard P. Association of primary pleural effusion lymphoma of T-cell origin and human herpesvirus 8 in a human immunodeficiency virus-seronegative man. Arch Pathol Lab Med 2001;125:1246-8.  Back to cited text no. 33
34.Ascoli V, Lo Coco F, Torelli G, Vallisa D, Cavanna L, Bergonzi C, et al.. Human herpesvirus 8-associated primary effusion lymphoma in HIV--patients: a clinicopidemiologic variant resembling classic Kaposi's sarcoma. Haematologica 2002;87:339-43.  Back to cited text no. 34
35.Buonaiuto D, Rossi D, Guidetti F, Vivenza D, Berra E, Deambrogi C, et al.. Human herpesvirus type 8-associated primary lymphomatous effusion in an elderly HIV-negative patient: clinical and molecular characterization. Ann Ital Med Int 2002;17:54-9.  Back to cited text no. 35
36.Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, et al.. Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood 2003;101:4115-21.   Back to cited text no. 36
37.Boulanger E, Hermine O, Fermand JP, Radford-Weiss I, Brousse N, Meignin V, et al.. Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV negative elderly patients. Am J Hematol 2004;76:88-91  Back to cited text no. 37
38.Munichor M, Cohen H, Sarid R, Manov I, Iancu TC. Human herpesvirus 8 in primary effusion lymphoma in an HIV-seronegative male. A case report. Acta Cytol 2004;48:425-30.  Back to cited text no. 38
39.Danese C, Angrisani L, Colotto M, Clarice A, Ferranti E. A five year follow-up of an HHV-8 related lymphoma in a HIV-negative elderly patient. Clin Ter 2004;155:543-6.  Back to cited text no. 39
40.Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, et al.. Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 2005;19:473-6.  Back to cited text no. 40
41.Halfdanarson TR, Markovic SN, Kalokhe U, Luppi M. A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative refractory to chemotherapy. Ann Oncol 2006;17:1849-50.  Back to cited text no. 41
42.Su YC, Chai CY, Chuang SS, Liao YL, Kang WY. Cytologic diagnosis of primary effusion lymphoma in a HIV-negative patient. Kaohsiung J Med Sci 2008;24:548-51.  Back to cited text no. 42
43.Siddiqi T, Joyce RM. A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab. Clin Lymphoma Myeloma 2008;8:300-4.  Back to cited text no. 43
44.Brimo F, Popradi G, Michel RP, Auger M. Primary effusion lymphoma involving three body cavities. Cytojournal 2009;6:21.  Back to cited text no. 44
[PUBMED]  Medknow Journal  
45.Stingaciu S, Ticchioni M, Sudaka I, Haudebourg J, Mounier N. Intracavitary cidofovir for human herpes virus-8-associated primary effusion lymphoma in an HIV-negative patient. Clin Adv Hematol Oncol 2010;8:367-74.  Back to cited text no. 45
46.Gandhi SA, Mufti G, Devereux S, Ireland R. Primary effusion lymphoma in an HIV-negative man. Br J Haematol 2011;155:411.   Back to cited text no. 46
47.Nakayama-Ichiyama S, Yokote T, Kobayashi K, Hirata Y, Hiraoka N, Iwaki K, et al.. Primary effusion lymphoma of T-cell origin with t(7;8)(q32;q13) in an HIV-negative patient with HCV-related liver cirrhosis and hepatocellular carcinoma positive for HHV6 and HHV8. Ann Hematol 2011;90:1229-31.  Back to cited text no. 47
48.Ganzel C, Rowe JM, Ruchlemer R. Primary effusion lymphoma in a HIV-negative patient associated with hypogammaglobulinemia. Am J Hematol 2011;86:777-81.  Back to cited text no. 48
49.Navasa M, Rimola A, Rodes J. Bacterial infections in liver disease. Semin Liver Dis 1997;17:323-33.  Back to cited text no. 49
50.Ohshima K, Ishiguro M, Yamasaki S, Miyagi J, Okamura S, Sugio Y, et al.. Chromosomal and comparative genomic analyses of HHV-8-negative primary effusion lymphoma in five HIV-negative Japanese patients. Leuk Lymphoma 2002;43:595-601.   Back to cited text no. 50
51.Venizelos I, Tamiolakis D, Lambropoulou M, Nikolaidou S, Bolioti S, Papadopoulos H, et al.. An unusual case of posttransplant primary effusion lymphoma with T-cell phenotype in a HIV-negative female, not associated with HHV-8. Pathol Oncol Res 2005;11:178-81.  Back to cited text no. 51
52.Kobayashi Y, Kamitsuji Y, Kuroda J, Tsunoda S, Uoshima N, Kimura S, et al.. Comparison of human herpes virus-8-related primary effusion lymphoma with human herpes virus-8-unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol 2007;117:132-44.  Back to cited text no. 52
53.Adiguzel C, Bozkurt SU, Kaygusuz I, Uzay A, Tecimer T, Bayik M. Human herpes virus 8-unrelated primary effusion lymphoma-like lymphoma: report of a rare case and review of the literature. APMIS 2009;117:222-9.  Back to cited text no. 53
54.Ferry JA, Harris NL. In Atlas of Lymphoid Hyperplasia and Lymphoma. In: Day L, editor. 1 st ed. Philadelphia, PA: W.B. Saunders Company; 1997. p. 130-2.   Back to cited text no. 54
55.Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist 2007;12:569-76.  Back to cited text no. 55
56.Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, et al.. Distribution of human herpesvirus-8 latenty infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 1999;96:4546-51.  Back to cited text no. 56
57.Matolcsy A, Nador RG, Cesarman E, Knowles DM. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol 1998;153:1609-14.   Back to cited text no. 57
58.Fais F, Gaidano G, Capello D, Gloghini A, Ghiotto F, Roncella S, et al.. Immunoglobulin V region gene use and structure suggest antigen selection in AIDS-related primary effusion lymphomas. Leukemia 1999;13:1093-9.  Back to cited text no. 58
59.Gaidano G, Gloghini A, Gattei V, Rossi MF, Cilia AM, Godeas C, et al.. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138 / syndecan-1 antigen. Blood 1997;90:4894-900.  Back to cited text no. 59
60.Carbone A, Gloghini A, Larocca LM, Capello D, Pierconti F, Canzonieri V, et al.. Expression profile of MUM1 / IRF4, BCL-6, and CD138 / syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744-51.  Back to cited text no. 60
61.Said JW, Shintaku IP, Asou H, deVos S, Baker J, Hanson G, et al.. Herpesvirus 8 Inclusions in primary effusion lymphoma. report of a unique case with T-cell phenotype. Arch Pathol Lab Med 1999;123:257-60.  Back to cited text no. 61
62.Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, et al. .A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J 2001;2:172-9.  Back to cited text no. 62
63.Chan AC, Chan JK, Yan KW, Kwong YL. Anaplastic large cell lymphoma presenting as a pleural effusion and mimicking primary effusion lymphoma. A report of 2 cases. Acta Cytol 2003;47:809-16.  Back to cited text no. 63
64.Brimo F, Michel RP, Khetani K, Auger M. Primary effusion lymphoma: a series of 4 cases and review of the literature with emphasis on cytomorphologic and immunocytochemical differential diagnosis. Cancer 2007;111:224-33.   Back to cited text no. 64
65.Nakatsuka S, Yao M, Hoshida Y, Yamagato S, Iuchi K, Aozasa K. Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 2002;20:4255-60.  Back to cited text no. 65


  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]

  [Table 1]

This article has been cited by
1 KSHV Viral Cyclin Interferes with T-Cell Development and Induces Lymphoma through CDK6 and Notch Activation in vivo
Pirita Pekkonen,Annika Järviluoma,Nadezhda Zinovkina,Anna Cvrljevic,Sonam Prakash,Jukka Westermarck,Gerard I Evan,Ethel Cesarman,Emmy W Verschuren,Päivi M. Ojala
Cell Cycle. 2014; : 00
[Pubmed] | [DOI]
2 Primary effusion lymphoma with aberrant T-cell phenotype in an iatrogenically immunosuppressed renal transplant male: Cytologic diagnosis in peritoneal fluid
A. Kalogeraki,V. Haniotis,M. Karvelas-Kalogerakis,I. Karvela-Kalogeraki,M. Psyllaki,D. Tamiolakis
Diagnostic Cytopathology. 2014; : n/a
[Pubmed] | [DOI]
3 result 1 Document Announcement of first time Cytojournal impact factor for 2012 coincides with Cytojournal decade celebration (2004-2013)
Authors of Document Shidham, V.B., Demay, R.M.
CytoJournal. 2013;


Previous article Next article


  Site Map | Copyright and Disclaimer
© 2007 - CytoJournal | A journal by Cytopathology Foundation Inc with Wolters Kluwer - Medknow
New version online since 1st July '08
Open Access